By Yafo Life Science
September 1st, 2021 (Shanghai) — We are glad to announce that Michael Aldridge, CEO of Hexima Limited (ASX:HXL) has been invited to showcase at ACCESS CHINA Biotech Forum on Thursday, September 23, 2021 at 8:00 p.m. Pacific Time (September 24, 2021 at 11:00 a.m. China Time). ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About Hexima Limited
Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
ACCESS CHINA Upcoming event
“ACCESS CHINA Biotech Forum @ The 16th China Pharma & MedTech BD Forum” will be held in Suzhou and online on September 23rd-30th, 2021. This conference is the largest ACCESS CHINA event of the year.
Register ACCESS CHINA online, please visit:
For more information, please contact: